ADDF awards $210,300 to Amicus Therapeutics to judge PCs for treating Alzheimer’s disease The Alzheimer’s Drug Discovery Foundation announced today that it has awarded a grant of $210,300 to Amicus Therapeutics to evaluate small-molecule, orally shipped pharmacological chaperone compounds as a novel strategy for treating Alzheimer’s disease. Amicus has discovered an apparent link between several lysosomal enzymes and accumulation of the beta-amyloid and p-tau deposits observed in the mind of Alzheimer’s individuals. This process may be broadly applicable to diseases where an increase in the activity of a specific protein might provide therapeutic benefit generic medications . Brandon Wustman, Basic principle Investigator on the grant and Director of Exploratory Biology at Amicus Therapeutics.
Funded by BCBSIL, the Collaborative use the American College of Surgeons National Medical Quality Improvement System to investigate the surgical methods and outcomes of participating hospitals, and identify specific improvements to reduce surgical complications, the space of inpatient stays, readmission deaths and rates. We're making an investment later on of health care quality for Illinois by partnering with Northwestern Medicine and the American College of Surgeons, said Carol Wilhoit, MD, MS, senior medical director of outcomes and quality for BCBSIL. This collaborative brings hospitals and quality improvement experts together as a team with the singular goal of improving surgical look after patients.